Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03001297 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT03001297 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 64 participants.
The verdict
NCT03001297, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
A Phase 1, single dose study with 4 cohorts of ascending doses and an optional Japanese cohort designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of MEDI5884 in healthy volunteers
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MEDI5884 Dose 1
- BIOLOGICAL MEDI5884 Dose 2
- BIOLOGICAL MEDI5884 Dose 3
- BIOLOGICAL MEDI5884 Dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-01-17 |
| Est. Completion | 2018-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03001297
The ClinicalTrials.gov registry entry for NCT03001297 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03001297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03001297 about?
NCT03001297 is a clinical study titled "Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884". A Phase 1, single dose study with 4 cohorts of ascending doses and an optional Japanese cohort designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of MEDI5884 in healthy volunteers
What is the current status of trial NCT03001297?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2017-01-17. Estimated completion is 2018-08-10.
What interventions are being tested in trial NCT03001297?
The interventions under investigation include: Placebo (BIOLOGICAL), MEDI5884 Dose 1 (BIOLOGICAL), MEDI5884 Dose 2 (BIOLOGICAL), MEDI5884 Dose 3 (BIOLOGICAL), MEDI5884 Dose 4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03001297?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.